Allison Whitten, PhD
Allison Whitten earned her PhD from Vanderbilt University in 2018 and continued her scientific training at Vanderbilt as a National Institute of Biomedical Imaging and Bioengineering (NIBIB) Postdoctoral Fellow. Her PhD and postdoctoral studies investigated the neurobiological causes of language impairments in neurological disorders. In 2020, she was awarded an AAAS Mass Media Fellowship to write for Discover Magazine. Her work has also appeared in WIRED, Quanta Magazine, Ars Technica, and more.
Articles by Allison Whitten, PhD
| 3 min read
The FDA approved Medtronic’s adaptive deep brain stimulation system, which delivers electrical stimulation in real time based on the brain’s state.
| 5 min read
What’s stopping major progress in the development of new drugs right now? Biotech leaders and researchers shared their thoughts.
| 4 min read
Uniquity Bio seeks to investigate compounds that might otherwise sit on the shelf forever. Their lead compound appears poised to prove their model works.
| 10 min read
Advances in GLP-1 research for diabetes and obesity, multiple sclerosis discoveries, and DNA editing are awarded in this year’s prestigious prize.
| 2 min read
Antibiotics target bacteria, but new work in mice shows they also harm the mucus layer that protects the intestinal lining from microbes.
| 3 min read
Vertex Pharmaceuticals’ drug, Journavx, blocks a sodium channel outside of the brain. Experts hope that this non-addictive pain drug may be the first of many.
| 6 min read
Judy Sebolt-Leopold and her team at MEKanistic Therapeutics developed a single molecule targeting two kinase enzymes that drive resistance to cancer therapies.
| 7 min read
Most cancer cells have the wrong number of chromosomes, known as aneuploidy. Scientists are finding ways to target this flaw with new treatments.
| 10+ min read
GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity, but they come with side effects. Physicians say the benefits outweigh the risks.
| 2 min read
Researchers revealed for the first time that CAR T cells can transfer their CAR molecules to regular T cells in a process known as trogocytosis.
| 8 min read
Lundbeck Therapeutics is testing a monoclonal antibody that targets a novel neuropeptide in a Phase 2b clinical trial.
| 4 min read
Pfizer researchers are developing new treatments to target breast cancer tumors that flourish in the presence of hormones.
| 2 min read
Using a sheep model, researchers developed an injectable biomaterial that interacts with nearby cells and recruits them to make new cartilage.
| 4 min read
Industry leaders name the clinical trials and developments they’re most excited to see in the new year.
| 5 min read
Industry leaders predict the most exciting advances in drug discovery and development in the coming year.
Page 1 of 3 - 39 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Unlocking laboratory efficiency: a complete guide to LIMS selection
Discover how to choose, implement, and optimize laboratory information management systems (LIMS) to streamline lab operations and ensure compliance.
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
